Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Panitumumab

(Vectibix®)

Vectibix®

Drug updated on 9/4/2024

Dosage FormInjection (intravenous; 100 mg/5 mL, 400 mg/20 mL [20 mg/mL] in a single-dose vial)
Drug ClassEpidermal growth factor receptor antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): in combination with FOLFOX for first-line treatment.
  • Indicated as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Vectibix (panitumumab) is indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): in combination with FOLFOX for first-line treatment; and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • The combination of FOLFOXIRI and anti-EGFR antibodies demonstrated a higher Objective Response Rate (ORR) of 85% (95% CI, 0.78-0.91) and a higher R0 resection rate (R0RR) of 42% (95% CI, 0.32-0.53) compared to FOLFOXIRI alone. Pooled ORR in the meta-analysis was 82% (95% CI, 76-88%), with an R0RR of 59% (95% CI, 49-68%) for colorectal liver metastasis (CLM).
  • Panitumumab supplementation improved ORR in patients with wild-type (WT) KRAS (RR = 1.70; 95% CI = 1.07–2.69) but did not significantly affect ORR in mutant KRAS patients (RR = 0.92; 95% CI = 0.79–1.08). The treatment did not notably impact progression-free survival (PFS) or overall survival (OS) in WT KRAS patients (PFS: RR = 0.94; 95% CI = 0.85–1.02, OS: RR = 0.86; 95% CI = 0.69–1.08).
  • The median PFS in the studies ranged from 9.5 to 17.8 months, with the pooled median PFS being 11.7 months. The median OS ranged from 24.7 to 62.5 months, with a pooled median OS of 31.9 months.
  • Common grade 3 and 4 adverse events associated with panitumumab supplementation include diarrhea (29%), neutropenia (28%), and skin toxicity (17%), with an overall increased incidence of these adverse events compared to control groups (RR = 1.17; 95% CI = 1.08–1.27).
  • The meta-analysis did not show a significantly increased risk of fatal adverse events (FAEs) for panitumumab, regardless of its use as first-line, second/further line, or adjuvant treatment compared to placebo or blank treatment.
  • There is no population type or subgroup information available in the reviewed studies.